Beta Thalassemia Major

• FDA approval · 2011-10-14
  FDA Approved: FERRIPROX — Original Application (Chiesi USA, Inc.)

  Ferriprox (deferiprone) has been approved by the FDA under an original application from Chiesi USA, Inc. for the treatment of iron overload …

• CLINICAL_TRIALS trial_result · 2011-07-29
  Clinical Trial Update: Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) [Phase 4]

  This Phase 4 extension study evaluates the efficacy and safety of deferasirox in transfusion-dependent beta-thalassemia patients with iron o…

• CLINICAL_TRIALS trial_result · 2011-07-26
  Clinical Trial Update: Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients [Phase 2, Phase 3]

  A Phase 2/3 clinical trial evaluates zoledronic acid to prevent bone loss after bone marrow transplantation in patients with beta-thalassemi…

• CLINICAL_TRIALS trial_result · 2009-10-21
  Clinical Trial Update: Therapeutic Effects of Silymarin in Patients With B-thalassemia Major [Phase 2, Phase 3]

  A clinical trial update reports on the investigation of silymarin for beta-thalassemia major with iron overload in Phase 2 and Phase 3 studi…

• FDA label_change · 2007-12-21
  FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for EXJADE (deferasirox) by Novartis Pharmaceuticals Corporation, updating the product labeling.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2007-04-20
  FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for EXJADE (deferasirox) submitted by Novartis Pharmaceuticals Corporation, resulting in an approved…